Stock DMYD B DIAMYD MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Diamyd Medical AB

Equities

DMYD B

SE0005162880

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
14.84 SEK +0.95% Intraday chart for Diamyd Medical AB +7.54% +125.88%
06-26 Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024 CI
05-16 Diamyd Medical AB Updates on the Registrational Phase 3 Trial CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
DIAMYD MEDICAL AB Stock Diamyd Medical AB
+125.88% 140M
D
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
B+
ARGENX SE Stock argenx SE
+18.95% 26.02B
B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
B+
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
C+
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DMYD B Stock
  4. Ratings Diamyd Medical AB